posted
ICBT hit hod of .017 from .0045. Finished .011 on great news. Low float. May have some more pop left in it imo.
Estimated Market Cap $1,136,020 as of Jul 6, 2009 Outstanding Shares 284,005,013 as of Jun 2, 2009 Authorized Shares 500,000,000 as of Oct 1, 2008 Float 33,977,044 as of Jun 1, 2009
Major Firms Eyeing CBMS Development of New Glaucoma Treatment
NEW YORK, MONTREAL and SAN DIEGO, CA, July 7, 2009 /PRNewswire-FirstCall via COMTEX/ -- Canadian Bio Med Systems Inc., a subsidiary of ICBS Ltd., (OTCPK: ICBT), and Ocular Therapeutics Inc. of San Diego California, announced that Ocular Therapeutics has signed non-disclosure agreements with two of the largest pharmaceutical firms in the world. These unnamed companies are interested in a new treatment approach in the largest of the ophthalmic markets. High Interest in a New Approach to Glaucoma Treatment
One of the reasons these large entities are so interested in this project is because of a recent article in the "Review of Ophthalmology" supports the development of a new class of glaucoma drugs now being tested by Canadian Bio Med Systems, Inc. (CBMS). The article was identified incorrectly as being from the "Survey of Ophthalmology" in an earlier release. The article entitled "Glaucoma Drugs: The Search for New Options" quotes David Epstein, MD, Chairman of Ophthalmology at Duke University School of Medicine in Durham North Carolina. Dr. Epstein points out that the approach of improving aqueous outflow in the eye is "the most logical approach to treating glaucoma"
Glaucoma is caused by an increase of intraocular pressure within the eye. The new compound being developed by CBMS in conjunction with Ocular Therapeutics, Inc. of California, specifically targets a portion of the eye, Schlemm's Canal, which is critical in achieving aqueous outflow and lowering intraocular pressure. This novel approach to treatment may require application of the drug every three months, or even less often, rather that twice per day. It could revolutionize the treatment for glaucoma.
Dr. Epstein points out the commercial aspects of such a potential drug that improves aqueous outflow by saying that when such a drug is developed "you will see every major pharmaceutical company jump on the bandwagon and want to have an outflow drug". Further he says, "Then in retrospect, every one will say 'Why didn't we work on this drug sooner'".
CBMS is completing the studies required to enter into human clinical trials in centers both in the United States and Canada.
The drug for the treatment of glaucoma is being developed by Daniel Stamer, PhD and Ronald Heimark, PhD at the University of Arizona. Glaucoma is a prevalent eye disease is one of the leading causes of blindness in the world. Patient compliance is a serious problem in glaucoma because of the frequency which conventional medication is required. The new drug being developed may change the paradigm of glaucoma therapy.
NB. This news release includes statements that constitute forward-looking statements. Please be aware that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary materially from those in the forward-looking statements as a result of any number of factors, including the risk factors contained in the Company's disclosure documents.
SOURCE ICBS Ltd.
www.prnewswire.com Copyright (C) 2009 PR Newswire. All rights reserved -0-
KEYWORD: Quebec INDUSTRY KEYWORD: FIN HEA
Posts: 712 | Registered: Mar 2006
| IP: Logged |
posted
BioSpec Global Solutions Inc., announced today a new R&D program for the analysis of Antibiotic resistant microbes Press Release Source: INTER CANADIAN BUSINESS SERVICE On 9:00 am EDT, Tuesday October 27, 2009 Buzz up! 0 Print Companies:Icbs Ltd New NEW YORK and MONTREAL, Oct. 27 /PRNewswire-FirstCall/ - BioSpec Global Solutions Inc., and partner - ICBS Ltd. (OTCPK: ICBT), announced today a new R&D project for a multiple test system for antibiotic resistant Microbes.
Related Quotes Symbol Price Change ICBT.PK 0.00 +0.00
{"s" : "icbt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""} BioSpec Global Solutions Inc., is to develop a multiple test system for the analysis of Antibiotic Resistant Microbes (ARMs) and Antibiotic Susceptible Microbes (ASMs) in clinical samples. The idea is to develop an apparatus with 6-8 sample tests in a single unit. A sample is divided into 6 (or 8)and are tested simultaneously. In each sample test vessel a specific antibiotic will be added which is generally prescribed by the doctors for suspected bacterial infection. As an average the test can be done in 3-4 hours. This will provide the doctor which antibiotic works for this infection or if the tested patient is carrying an ARM (antibiotic resistant bacteria). If the antibiotic works, that test sample will not show growth of the microbe in question. Putting these in a doctor's office, they can test and make a decision as to how to treat the patient in about 4 hours. Currently, the doctors will have to take a sample and send to a lab and wait for 3-5 days to know what type of microbe they are dealing with. Meanwhile, they may have to prescribe an antibiotic hoping that will work. This new technology prevents prescribing unwanted antibiotic usage which is the root cause of creating these ARM's in the first place.
The TOGS 9000 is a bio-photonic incubation/detection instrument which quantifies microbial contamination. The analysis results can be obtained directly on-site through a computer or can be directly connected and controlled by an appropriate laboratory and or regulatory authority in a secure monitoring system using 'AGACSS(TM)' software and the internet.
The company holds worldwide patents on the TOGS 3000 and 9000.
NB. This news release includes statements that constitute forward-looking statements. Please be aware that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may vary materially from those in the forward-looking statements as a result of any number of factors, including the risk factors contained in the Company's disclosure documents.
Posts: 43 | From: new jersey | Registered: Sep 2009
| IP: Logged |
posted
China contract close to completion. PR should be coming out soon. this is a great entry point after Friday's shake
Posts: 4 | From: toronto | Registered: Jan 2010
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
